Top 8 Trending AI News Updates Investors Should Not Miss

5. Myriad Genetics Inc. (NASDAQ:MYGN)

Number of Hedge Fund Holders: 21

Myriad Genetics Inc. (NASDAQ:MYGN) develops precision medicine and molecular diagnostic testing solutions to perceive how genes affect diseases, help physicians evaluate associated risks, and guide treatment decisions to uplift patient outcomes at lower costs.

On February 24th, the company announced executing an agreement with PATHOMIQ Inc. to license the PATHOMIQ_PRAD AI tech platform, which will help doctors make well-informed pre- and post-surgery medical decisions for prostate cancer. PATHOMIQ Inc. innovates AI-powered prognostic and predictive tests to improve access to personalized medicine.

“Along with our Prolaris® Prostate Cancer Prognostic Test, we are pleased to leverage PATHOMIQ’s prognostic and predictive capabilities across different phases of the patient journey in prostate cancer. Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes. This partnership is the latest step in the strategic expansion of Myriad’s oncology portfolio. Our molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer.”

-said George Daneker, Jr., President and Chief Clinical Officer of Oncology at Myriad Genetics Inc.